Adalimumab News and Research

RSS

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

Dermcidin, an anti-microbial peptide normally found in human sweat, may play a role in the pathogenesis of this chronic skin disease hidradenitis suppurativa, according to a research team from the George Washington University.

26 Apr 2019

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

Dr. John McCafferty celebrates the success of phage display technology with Nobel Prize in Chemistry Laureates.

From FairJourney Biologics 12 Dec 2018

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

29 Nov 2018

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Study offers new hope for people with disabling Dupuytren's disease

Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.

9 Jul 2018

Study: Psoriasis patients taking Humira show no change in aortic inflammation

An antibody used to treat the skin disease psoriasis and other chronic autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease has no effect on aortic inflammation – a key marker of future risk of major cardiovascular events – unlike other antibodies that target different aspects of the immune system.

18 May 2018

Psoriasis drug also effective at reducing aortic inflammation

Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.

18 Feb 2018

Finger prick test offers opportunity to simplify therapeutic drug monitoring of biologics

A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw.

9 Aug 2017

Genetic test to predict IBD severity in children

Inflammatory bowel disease (IBD) is a chronic relapsing inflammation of the gastrointestinal tract with abdominal pain and diarrhea being the most common symptoms. It can be challenging to diagnose as gastrointestinal complaints mimicking IBD are common.

26 Jul 2017

Researchers show effective oral treatment option for patients with rheumatoid arthritis

Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well.

19 Jun 2017

FOI technique found to be effective in detecting joint inflammation in children

The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.

14 Jun 2017

Clinical trial discovers drug combination that could help children with arthritis

A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the Universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.

27 Apr 2017

Study shows efficacy of biologics for mucosal healing in Crohn's disease and ulcerative colitis

Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery.

22 Mar 2017

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab).

16 Nov 2016

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

23 Sep 2016

Patients with noninfectious uveitis can get effective treatment from corticosteroid alternative

Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn's disease, according to a study led by a Duke Health researcher.

8 Sep 2016

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform.

2 Aug 2016